Wall Street Journal reporting shows that blood-testing startup Theranos, once valued at $9 billion, ran most tests on conventional machines. Its founder is later convicted of defrauding investors.
Contested history
Consensus: Theranos's device could run only a limited set of tests and was less reliable than claimed; founder Elizabeth Holmes was convicted in 2022 of defrauding investors.
The founder knowingly misled investorsEstablished
A jury convicted her of conspiracy and three counts of wire fraud involving investors.
She also defrauded patientsDebated
The jury acquitted her on the patient counts, although regulators found the lab's results put patients at risk.
The company was a victim of the press and competitorsUnsupported
Federal lab inspectors found serious deficiencies in 2016, independent of the reporting.